Skip to content

Research paper

Omega-3 and omega-6 polyunsaturated fatty acids for dry eye disease.

The Cochrane database of systematic reviews
Q1
Dec 2019
Citations: 87
Influential: 2
Systematic Reviews / Meta-Analyses
93

Study answer

What this study found

Overall, the evidence was mixed and generally of low to moderate certainty. For long-chain omega-3 versus placebo, there was no consistent improvement in subjective dry eye symptoms, although some trials showed modest benefits in objective signs such as tear production, tear osmolarity, and TBUT, with substantial heterogeneity. Adding omega-3 to conventional therapy may improve symptoms versus conventional therapy alone, but the certainty was low. When omega-3 was compared with omega-6, some analyses favored omega-3 for symptom improvement. The authors concluded that heterogeneity in…

Study & population
Systematic review and meta-analysis of adults with dry eye disease from diverse causes and settings, including Sjögren's syndrome, meibomian gland dysfunction, post-LASIK or post-cataract surgery, computer vision syndrome, contact lens-related dry eye, rosacea, and other ocular or systemic comorbidities.
Intervention
Oral long-chain omega-3 polyunsaturated fatty acid supplements, and in some comparisons omega-6 preparations or omega-3 plus conventional therapy, were evaluated for dry eye disease.
Key limitation
Substantial heterogeneity in supplement formulations, doses, durations, and patient populations limited pooling and interpretation.
View sourceOpen PDF

Original abstract

BACKGROUND Polyunsaturated fatty acid (PUFA) supplements, involving omega-3 and/or omega-6 components, have been proposed as a therapy for dry eye. Omega-3 PUFAs exist in both short- (alpha-linolenic acid [ALA]) and long-chain (eicosapentaenoic acid …